期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
State of the art biological therapies in pancreatic cancer 被引量:3
1
作者 mariacristina di marco elisa grassi +8 位作者 sandra durante silvia vecchiarelli andrea palloni marina macchini riccardo casadei claudio ricci riccardo panzacchi donatella santini guido biasco 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2016年第1期55-66,共12页
Pancreatic ductal adenocarcinoma(PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstra... Pancreatic ductal adenocarcinoma(PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib(a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials(closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment. 展开更多
关键词 PANCREATIC cancer Molecular characterization TARGETED therapy EPIDERMAL growth factor receptorinhibitors EMBRYONIC pathway INHIBITORS Antiangiogenictherapies
下载PDF
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
2
作者 Mariacristina Di Marco Riccardo Carloni +16 位作者 Stefania De Lorenzo Cristina Mosconi Andrea Palloni elisa grassi Daria Maria Filippini Angela Dalia Ricci Alessandro Rizzo Alessandro Di Federico Donatella Santini Daniela Turchetti Claudio Ricci Carlo Ingaldi Laura Alberici Francesco Minni Rita Golfieri Giovanni Brandi Riccardo Casadei 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2020年第12期1456-1463,共8页
BACKGROUND Pancreatic mucinous cystadenocarcinoma(MCAC)is a rare malignancy with a poor prognosis when it presents metastases at diagnosis.Due to its very low incidence,there are no clear recommendations for the treat... BACKGROUND Pancreatic mucinous cystadenocarcinoma(MCAC)is a rare malignancy with a poor prognosis when it presents metastases at diagnosis.Due to its very low incidence,there are no clear recommendations for the treatment of advanced disease.Olaparib(an oral PARP inhibitor)has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline BRCA1/2 mutations.Herein,we report the first case of a germline BRCA1 mutated unresectable MCAC which was effectively treated with olaparib.CASE SUMMARY A 41-year-old woman,without personal or family history of cancer,was diagnosed with ovarian and peritoneal metastases of MCAC.She underwent 12 cycles of gemcitabine plus oxaliplatin(GEMOX)obtaining a partial response and allowing radical surgery.One year later,local recurrence was documented,and other 12 cycles of GEMOX were administered obtaining a complete response.Seven years later,another local recurrence,not amenable to surgical resection,was diagnosed.She started FOLFIRINOX(oxaliplatin,irinotecan,leucovorin and fluorouracil),obtaining a partial response after 8 cycles.Given the excellent response to platinum-based chemotherapy,BRCA testing was performed,and a BRCA1 germline mutation was detected.She was switched to maintenance olaparib due to chemotherapy-related toxicities and achieved an almost complete metabolic response,with a reduction in the diameter of the lesion,after three months of therapy.CONCLUSION The current case suggests the beneficial effect of olaparib in BRCA mutated MCAC.However,further studies are required. 展开更多
关键词 Mucinous cystadenocarcinoma Pancreatic cancer BRCA1 gene OLAPARIB Case report
下载PDF
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation:A case report
3
作者 Mariacristina Di Marco Riccardo Carloni +7 位作者 Stefania De Lorenzo elisa grassi Andrea Palloni Francesca Formica Stefano Brocchi Daria Maria Filippini Rita Golfieri Giovanni Brandi 《World Journal of Clinical Cases》 SCIE 2020年第7期1241-1250,共10页
BACKGROUND Pancreatic acinar cell carcinoma (PACC) is a rare type of malignant pancreatic cancer that represents approximately 1%of all pancreatic neoplasms.Due to its very low incidence,only a few retrospective studi... BACKGROUND Pancreatic acinar cell carcinoma (PACC) is a rare type of malignant pancreatic cancer that represents approximately 1%of all pancreatic neoplasms.Due to its very low incidence,only a few retrospective studies are available.Although surgery is the first choice for treatment,most patients experience recurrence(mainly in the liver) and there are no clear recommendations for patients with advanced disease.CASE SUMMARY We report two patients with PACC treated with sturgery who experienced tumour recurrence in the liver.Patient 1 carried a germline mutation in the APC gene.Both patients were treated with gemcitabine plus oxaliplatin and gemcitabine plus capecitabine as first-and second-line therapies,respectively.After a favoturable response to chemotherapy,the patients underwent radiofrequency ablation of the remaining liver metastases.For patient 1,we documented a relapse in the liver after a disease-free period of 9 mo,and treatment with gemcitabine plus capecitabine was restarted.The patient achieved a complete response,and he remains alive without evidence of disease recurrence after six years.After radiofrequency ablation,patient 2 experienced disease-free survival for 21 mo,when peritoneal relapse was diagnosed and treated with chemotherapy.The patient achieved a stable disease state for nearly two years;nevertheless,further progressive disease was documented,and he died seven years after the first relapse.CONCLUSION PACC presents different biological behaviours than pancreatic adenocarcinoma.Multidisciplinary treatment involving local ablative therapies may be considered for PACC. 展开更多
关键词 Acinar cell CARCINOMA PANCREAS Liver METASTASIS RADIOFREQUENCY ablation Case report
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部